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and COX-2 inhibitorsAbstract Aminoacetylenic isoindoline-1,3-dione derivatives were synthesized from the reaction of
potassium phthalimide with propargyl bromide to generate 2-(prop-2-yn-1-yl)isoindoline-1,3-dione
(ZM1). Treatment of 2-(prop-2-yn-1-yl)isoindoline-1,3-dione with appropriate cyclic amines
through Mannich reaction yielded ﬁve desired aminoacetylenic isoindoline-1,3-diones called,
ZM2–ZM6. The IR, NMR and elemental analysis were consistent with the assigned structures.
These synthetic compounds, except ZM6, produced signiﬁcant (p< 0.05–0.01) dose-related inhibi-
tion of carrageenan-induced edema in rats following 3 and 5 h post-oral administration of 5, 10, and
20 mg/kg doses. The percent inhibition of edema varied between the compounds at 10 mg/kg dose
being ZM3 > ZM5 > ZM4 > ZM2. These percent inhibitions for ZM3 and ZM5 were not signif-
icantly different than those of induced by Ibuprofen, Diclofenac and Celecoxib. At 20 mg/kg dose,
ZM4 produced a statistically signiﬁcant reduction of inﬂammation (p< 0.01) 1 h following admin-
istration and persisted for 5 h. Furthermore, all the compounds showed inhibition of COX-1 and
COX-2 with maximum inhibition at 5 lM. However, the inhibition values were less than Diclofenac
Synthesis and pharmacological evaluation of aminoacetylenic isoindoline-1,3-dione derivatives 1025and Celecoxib. The best response was by ZM4 for COX-2 inhibition ranging from 28%, 91%, and
44%, for 2, 5, and 10 lM, respectively. Other ZM compounds such as ZM2, ZM3, and ZM5 exhib-
ited inhibitory responses for COX-2 more than COX-1 at 5 lM. These results indicate that these
ZM compounds have the potential to become anti-inﬂammatory drugs following further pharma-
cological and toxicological evaluations.
ª 2011 Production and hosting by Elsevier B.V. on behalf of King Saud University.Table 1 Compounds with analgesic and anti-inﬂammatory
activities.
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Acetylenic aspirin analogue 1. Introduction
Non-steroidal anti-inﬂammatory drugs (NSAIDs) are widely
used to treat acute or chronic inﬂammation and offer symptom-
atic pain relief (Bhati and Kumar, 2008; Lombardino, 1985).
Conventional NSAIDs act by non-selective inhibition of cyclo-
oxygenase (COX) enzymes, which are involved in prostaglan-
dins (PGs) biosynthesis from arachidonic acid (Dannhardi
and Kiefer, 2001; Carter, 2000; Farooqui et al., 2009). There
are at least two main mammalian COX isoforms, COX-1 and
COX-2. Constitutive COX-1 has a housekeeping function;
including gastro-protective and kidney function regulation
PGs, whereas COX-2 is induced in inﬂammatory cells and
generate PGs that help mediate the inﬂammatory response
(Dannhardi and Kiefer, 2001; Carter, 2000; Farooqui et al.,
2009). Classical NSAIDs such as Aspirin and Ibuprofen are
selective inhibitors of COX-1 isoenzyme and cause gastric
failure like bleeding and ulcer. In contrast, selective COX-2
inhibitors such as Celecoxib, Rofecoxib, and Valdecoxib exert
anti-inﬂammatory and analgesic activity with markedly less
gastrointestinal toxicity than the traditional NSAIDs (Xie
et al., 1991; Ranatunge et al., 2004). However, the worldwide
withdrawal of Rofecoxib (Vioxx) is because of evidence of in-
creased risk to cardiovascular events in patients with heart dis-
ease. The latter patients are more prone to myocardial
infarction. This may be due to the thromboxane A2/PGI2
imbalance created by selective COX-2 inhibitors (Orjales
et al., 2008; Sharma and Ray, 2008; Reddy et al., 2008). In
order to abolish or decrease these clinical side effects, a current
strategy consists of designing COX inhibitors with different
chemical structure from the already known COX inhibitors.
We are interested in phthalimide derivative, since some studies
in 2005 revealed that thalidomide was effective in treatment of
many inﬂammatory processes (Sano et al., 2005). More recently
oxadiazolo-phthalimides showed a signiﬁcant analgesic and
anti-inﬂammatory properties (Kuogsgaard-Larsen and
Ulfmadsen, 2002; Desteven’s, 1965; Chen et al., 2005). This
indicates that the incorporation of phthalimide group in our
designed compounds is safe and could contribute to anti-
inﬂammatory activities. Furthermore, N-2-(2-pyridylethyl)
phthalimide showed a signiﬁcant analgesic activity (Desteven’s,
1965). The insertion of acetylenic group in aspirin analogue
resulted in higher potency and selectivity toward COX-2 inhibi-
tion (Table 1). These structural observations in regard to the
pharmacological effect of acetylenic groups and phthalimide
promoted our interest to synthesize a novel series of N-[4-(t-
amino-yl)-but-2-yn-1-yl]isoindoline-2,3-diones (Table 2) and
investigating the anti-inﬂammatory activity and selectivity of
these compounds to COX-1 and COX-2 enzymes. This unique
combination represents a new series of compounds as anti-
inﬂammatory agents; differ from the generally used drugs on
the market with acidic, enolic, sulfonamide or sulfon groups
in their structures.2. Experimental
2.1. Chemistry
Melting points were measured by Fischer–Johns melting Point
Apparatus and DSC measured were carried out by using DSC-
50 (Shimadzu, Japan). Infrared spectra (IR) were recorded, as
potassium bromide (KBr) discs on a Nicolet Impact-400 FT-
IR spectrophotometer. 1H and 13C NMR were acquired with
the aid of Bruker-DPX 300 MHz spectrometers with DMSO-
d6 as solvents and TMS as an internal standard. Elemental
analysis was obtained using EU Elemental Analyzer.
Table 2 The synthesized aminoacetylenic isoindoline-1,3-dione compounds.
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(ZM1)
A solution of potassium phthalimide (1.87 g, 0.01 mol) in
30 ml benzene was reﬂuxed to 40 C, propargyl bromide
(1.4 g, 0.01 mol) was added drop wise to the solution during
30 min. The mixture was stirred for 2 h and then ﬁltered.
The solvent was removed under reduced pressure to afford
the desired compound (1.2 g, 66.6%) as a white crystalline
powder, m.p. (152–153) C. IR (KBr, cm1): 3294 („CH,
stretch), 3049 (ArH, stretch), 2245 (C„C, stretch), 1766,
1720 (C‚O, stretch), 1612, 1553, 1396 (Ar, C‚C, stretch),
1000–900 (C‚C, bending), 802, 694, 632, (ArH, bending).
1H NMR (DMSO-d6): d, 3.24 (t, 1H, J= 2.01 Hz, C„CH),
4.32 (d, 2H, J= 2.01 Hz, N–CH2–C„), 7.76–7.8 (m, 4H,
ArH). 13C NMR (DMSO-d6): d, 27 (C
5), 74 (C7), 78 (C6),
123 (C1,1
0
), 131 (C3,3
0
), 135 (C2,2
0
), 167 (C4,4
0
). Anal. Calcd.
(C11H7NO2): C, 73.50; H, 3.78; N, 7.56. Found: C, 73.4; H,
3.75; N, 7.52.2.3. Synthesis of N-[4-(pyrrolidino-1-yl)-but-2-yn-1-
yl]isoindoline-1,3-dione (ZM2)
A mixture of 2-[prop-2-yn-1-yl]isoindoline-1,3-dione (0.9 g,
0.1 mol), paraformaldehyde (0.15 g, 0.12 mol), pyrrolidine
(0.78 g, 0.11 mol) and cuprous chloride catalytic amount
(0.03 g) in peroxide-free dioxane 20 ml was reﬂuxed for
1 h. After cooling, 100 ml of water was added and the crude
product recrystallized from ethanol (5–10 ml) afforded the
desired compound (1.6 g, yield 61.9%), m.p. (112–113) C.
IR (KBr, cm1): 2931, 2845 (ArH, stretch), 2260 (C„C,
stretch), 1720, 1755 (C‚O, stretch), 1612.5, 1458 (Ar,
C‚C, stretch), 1080, 9412 (Ar, C‚C, bending), 895, 725,
640 (ArH, bending). 1H NMR (DMSO-d6): d, 1.9 (m, 4H,
10CH2–
100CH2), 1.6 (m, 4H,
9CH2–
9CH2), 3.05 (t, 2H,
J= 2.4 Hz, „C–8CH2–N), 3.66 (t, 2H, J= 2.4 Hz,
5CH2),
7.7–8 (m, 4H, ArH). 13C NMR (DMSO-d6): d, 20 (C
12),
24 (C11), 26.2 (C10
0
), 27.4 (C10), 54.4 (C9
0
), 43.8 (C9), 52.9
(C8), 54.5 (C5), 78.2 (C6), 79.5 (C7), 123.8 (C1,1
0
), 131.9
(C3,3
0
), 135.2 (C2,2
0
), 167.2 (C4,4
0
). Anal. Calcd.
(C16H16N2O2): C, 72.97; H, 6.75; N, 9.41. Found: C,
72.14; H, 6.72; N, 9.43.2.4. Synthesis of N-[4-piperidino-1-yl]-but-2-yn-1-
yl]isoindoline-1,3-dione (ZM3)
ZM3 was prepared following the same procedure for the syn-
thesis of ZM2 afforded (1.7 g, 63%) as a white crystalline
compound, m.p. (83–84) C. IR (KBr, cm1): 2931 (ArH,
stretch), 2252 (C„C, stretch), 1720, 1755 (C‚O, stretch),
1612, 1458 (Ar, C‚C, stretch), 995, 941.2 (C‚C, bending),
864, 786, 717, (Ar, H, bending). 1H NMR (DMSO-d6): d,
1.53 (m, 2H, 11CH2–C), 1.59 (m, 4H, C–
10CH2–
100CH2),
1.64 (m, 4H, 9CH2–
90CH2), 3.39 (t, 2H, J= 2.4 Hz,
8CH2–
N), 3.66 (t, 2H, J= 2.4 Hz, 5CH2), 7.7–8 (m, 4H, ArH).
13C NMR (DMSO-d6): d, 24.03 (C
11), 25.8 (C 10,10
0
), 27.1
(C9,9
0
), 52.9 (C8), 66.6 (C5), 74.2 (C6), 79.3 (C7), 123.8
(C1,1
0
), 131.9 (C3,3
0
), 135.2 (C2,2
0
), 167 (C4,4
0
). Anal. Calcd.
(C17H18N2O2): C, 72.34; H, 6.30; N, 9.90. Found: C, 72.31;
H, 6.27; N, 9.92.2.5. Synthesis of N-[4-(2-methyl piperidino-1-yl)-but-2-yn-1-
yl]isoindoline-1,3-dione (ZM4)
ZM4 was prepared following the same procedure described for
the synthesis of ZM2 afforded (1.8 g, 63.1%) as a white crystal-
line compound, m.p. (105–107) C. IR (KBr, cm1): 2931, 2845
(ArH, stretch), 2260 (C„C, stretch), 1720, 1755 (C‚O,
stretch), 1612.5, 1458 (Ar, C‚C, stretch), 1080, 9412 (Ar,
C‚C, bending) 895, 725, 640 (ArH, bending). 1H NMR
(DMSO-d6): d, 1.12 (d, 3H, J= 4.2 Hz,
12CH3), 1.5 (m, 6H,
10CH2–
100CH2–
11CH2), 1.5 (m, 2H,
9CH2), 1.64 (m, 1H,
90CH), 3.05 (t, 5CH2, J= 2.4 Hz), 3.66 (t, 2H,
5CH2,
J= 2.4 Hz), 7.7–8.0 (m, 4H, ArH). 13C NMR (DMSO-d6): d,
20.0 (C12), 24 (C11), 26.2 (C10
0
), 27.4 (C10), 43.8 (C9
0
), 52.9
(C8), 54.5 (C5), 78.2 (C6), 79.5 (C7), 123.8 (C1,1
0
), 131.9 (C3,3
0
),
135.2 (C2,2
0
), 167.2 (C4,4
0
). Anal. Calcd. (C18H20N2O2): C,
72.97; H, 6.75; N, 9.41. Found: C, 72.92; H, 6.73; N, 9.42.
2.6. Synthesis of N-[4-(2-azepan-1-yl)-but-2-yn-1-
yl]isoindoline-1,3-dione (ZM5)
The title compound was prepared to according to synthetic
procedure described for ZM2, affording (1.8 g, 62.5%) as a
white crystalline product, m.p. (72–75) C. IR (KBr, cm1):
2924, 2831 (ArH, stretch), 2225 (C„C, stretch), 1712, 1755
(C‚O, stretch), 1612, 1465, 1319 (Ar, C‚C, stretch), 1111,
1087, 941 (Ar, C‚C, bending), 840, 794, 717 (ArH, bending).
1H NMR (DMSO-d6): d, 1.2–1.4 (m, 8H,
10CH2–
100CH2–
11
CH2–
110CH2), 1.6 (m, 4H,
9CH2–
90CH2), 3.03 (t, 2H,
J= 2.4 Hz, –8CH2), 3.46 (t, 2H, J = 2.4 Hz, –
6CH2–), 3.66
(t, 2H, J = 4.04 Hz, N–CH2–C„), 7.7–8 (m, 4H, ArH).
13C
NMR (DMSO-d6): d, 26.8 (C
11,110), 27.4 (C10,10
0
), 28.15
(C9,9
0
), 47.7 (C8), 54.7 (C5), 78.5 (C7), 80.8 (C6), 123.8 (C1,1
0
),
131.9 (C3,3
0
), 135.1 (C2,2
0
), 167.2 (C4,4
0
). Anal. Calcd.
(C18H20N2O2): C, 72.97; H, 6.75; N, 9.45; O, 10.81. Found:
C, 72.94; H, 6.79; N, 9.4.
2.7. Synthesis of N-[4-(2,6-dimethylpiperidino-1-yl)-but-2-yn-
1-yl]isoindoline-1,3-dione (ZM6)
ZM6 was prepared following the same procedure described for
the synthesis of ZM2 afforded (1.6 g, 52%) as a white crystalline
compound, m.p. (132–134) C. IR (KBr, cm1): 3030, 2931
(ArH, stretch), 2250 (C„C, stretch), 1750, 1720 (C‚O, stretch),
1612, 1465, 1390 (Ar, C‚C, stretch), 1100, 1085, 942 (Ar,C‚C,
bending), 840, 794, 717 (ArH, bending). 1H NMR (DMSO-d6):
d, 1.14 (d, 3H, J= 4.4 Hz, 12CH3), 1.14 (d, 3H, J= 4.2 Hz,
120CH3), 1.5 (m, 6H,
10CH2–
11CH2–
100 CH2), 1.80 (m, 2H,
9CH–9
0
CH), 3.4 (t, 2H, J= 2.4 Hz, 8CH2), 3.68 (t, 2H, J
= 2.4 Hz, 5CH2), 7.6–7.8 (m, 4H, ArH).
13C NMR (DMSO-
d6): d, 22.02 (C
12), 24.03 (C11), 25.8 (C10,10
0
), 27.1 (C9,9
0
), 52.9
(C8), 66.6 (C5), 74.2 (C6), 79.3 (C7), 128.8 (C2,2
0
), 131.9 (C3,3
0
),
135.2 (C1,1
0
), 167.0 (C4,4
0
). Anal. Calcd. (C19H22N2O2): C,
73.54; H, 7.09; N, 9.03. Found: C, 73.52; H, 7.07; N, 9.06.
3. Pharmacology
3.1. Animals
Male Sprague–Dawley rats (7–9 weeks old) were obtained
from Yarmouk University animal house unit (Irbid, Jordan).
1028 J.A. Al-Qaisi et al.Animals were housed at the Petra University animal facility in
a 12 h light/dark cycle and a constant temperature of 22 C.
All animals were acclimatized for 10 days prior to experiments
with free access to standard diet and drinking water. All ani-
mal experiments were performed in compliance with relevant
laws and institution guidelines.
3.2. Anti-inﬂammatory activity
The paw edema was induced by subcutaneous injection of
0.1 ml of 1% carrageenan solution into the plantar region of
the left hind paw of rats. The thickness of edema was measured
and recorded for each rat at 1, 3 and 5 h intervals, using an
electronic caliper (Mitutouo Corp., Japan). Different doses
of the tested compounds (0, 5, 10 and 20 mg/kg) in comparison
with Ibuprofen (5 and 10 mg/kg), Diclofenac (5 and 10 mg/kg),
and Celecoxib (3, 6 and 10 mg/kg) were given to the rats by
oral gavages 1 h prior to the administration of carrageenan.
The percent inhibition of paw edema thickness was calculated
using the following formula:
Percent inhibition ¼ 100 ½1 ðx2  x1Þ=ðy2  y1Þ
where x1 is the thickness of paw of rats before administration
of carrageenan and test or reference compounds, x2 is the
thickness of paw of rats after administration of carrageenan
in the test group, y1 is the thickness of paw of rats before
the administration of carrageenan in the control group and
y2 is the thickness of paw of rats after administration of carra-
geenan in the control group.
3.3. COX-1 and COX-2 inhibition assay
This assay measures directly prostaglandin (PGF2a) produced
by Sncl2 reduction of Cox-derived prostaglandin H synthase
(Caynman, Chemical Co., MI, USA). Brieﬂy, the PGF2a are
produced using ovine Cox 1 and human recombinant Cox 2,
arachidonic acid and heme in a reaction buffer (0.1 M Tris–
HCl, pH 8.0 containing 5 mM EDTA and 2 mM phenol).
The reaction is stopped by adding 1 M HCl followed by add-
ing saturated stannous chloride solution which is used to re-
duce PGH2 produced in the COX reaction to more stable
PGF2. The produced PGF2a was then assayed by an enzyme
immunoassay using a capture assay mouse anti-rabbit IgG
(captured antibody) for rabbit anti-prostaglandin antiserum.
Prostaglandin standards (15.6–2000 pg/ml) were used to con-
struct a standard curve, and prostaglandin tracer was usedN K
O
O
Br CH2 C CH
H CH
O
(CH2)nNH
CuCl
N
O
O
CH
+
+
Dioxane
ZM 2 - 6
Schemeto establish a competitive type of assay. After 18 h of incuba-
tion, plates were washed and Ellman’s Reagent was added.
The intensity of color was measured at a 405 nm using SCO
GmbH (Dingelstadt, Germany) ELISA Plate Reader. The
absorbance was transformed to pg/ml of PGF2a using stan-
dard curve computed on excel after transforming values to
% binding or (B/Bo) and present them on log–log graph
paper.
3.4. Data analysis
The overall differences between the treated groups were ana-
lyzed using one way ANOVA with Dunnett’s post hoc test.
The level of signiﬁcant difference was deﬁned as p< 0.05.
4. Results
4.1. Chemistry
The desired compounds listed in Table 2 were synthesized
through the following steps: potassium phthalimide was trea-
ted with propargyl bromide in benzene under reﬂux yielded
the appropriate 2-(prop-2-yn-1-yl)isoindoline-1,3-dione. The
Mannich reaction of 2-(prop-2-yn-1-yl)isoindoline-1,3-dione
(ZM1) with paraformaldehyde and appropriate amines in per-
oxide-free dioxane with catalytic amount of cuprous chloride
generated the designed aminoacetylenic isoindoline deriva-
tives: ZM2, ZM3, ZM4, ZM5 and ZM6 (Table 2). The IR,
1H NMR, 13C NMR spectra, DEPT 135, DEPT 90, and ele-
mental analyses were consistent with the all assigned structures
as shown in the experimental part (see Scheme 1).
4.2. Pharmacology
The acute anti-inﬂammatory activity of ZM2, ZM3, ZM4 and
ZM5 showed to be effective, with varying potencies. ZM6 was
inactive in reducing any inﬂammatory caused by carrageenan-
induced edema, for this reason it was excluded from testing its
inhibitory activity against COX-1 and COX-2. ZM2 at doses
of 10 and 20 mg/kg produced signiﬁcant dose-dependent inhi-
bition of inﬂammation (in the range from 22% to 57%) after 3
and 5 h post-carrageenan administration (p< 0.05). This com-
pound at 20 mg/kg, showed equipotent activity (p> 0.05) to
that of Ibuprofen (10 mg/kg), Diclofenac (10 mg/kg) and Cele-
coxib (12 mg/kg) at 3 and 5 h post-administration (Table 3).
On the other hand, ZM3 exhibited more inhibitory activityN
O
O
CH2 C CH
2 C C CH2 (CH2)nN
ZM1
1
Table 3 The percent of inhibition of carrageenan-induced inﬂammation produced by ZM compounds after oral administration.
Compound Dose (mg/kg) Percent of inhibition of carrageenan-induced inﬂammation after time of administration of ZM compoundsa
1 h 3 h 5 h
ZM2 5 17.0 ± 0.1 22.0 ± 1.3 22.0 ± 1.2
10 17.0 ± 0.1 23.0 ± 1.5 38.0 ± 1.5b
20 2.3 ± 0.3 42.0 ± 3.1b 57.0 ± 4.8b
ZM3 5 4.0 ± 1.0 44.0 ± 4.2b 60.5 ± 4.8b,c
10 21.0 ± 1.2 58.0 ± 4.8b 61.2 ± 8.2b,c
20 19.5 ± 1.1 53.0 ± 4.1b 72.3 ± 5.1b,c
ZM4 5 11.0 ± 0.1 21.0 ± 1.1 27.0 ± 1.4
10 21.1 ± 0.3 3.5 ± 0.5 40.0 ± 1.6b
20 73.0 ± 5.1b 58.0 ± 4.9b 76.0 ± 5.2b
ZM5 5 23.0 ± 1.2 45.0 ± 10b 48.0 ± 4.6b
10 19.5 ± 1.1 23.0 ± 1.2 49.5 ± 4.8b
20 31.0 ± 1.5b 68.0 ± 5.2b 69.0 ± 5.4b
Ibuprofen 5 19.5 ± 1.1 37.5 ± 3.5b 27.0 ± 3.9
10 40.6 ± 2.3b 38.0 ± 3.4b 40.6 ± 5.6b
Diclofenac 5 5.0 ± 1.2 40.5 ± 3.9b 56.0 ± 3.9b
10 0.5 ± 0.1 38.0 ± 4.6b 40.6 ± 3.5b
Celecoxib 3 11.5 ± 1.5 35.0 ± 3.3b 38.0 ± 4.1b
6 29.4 ± 3.8 33.0 ± 3.1b 47.0 ± 4.6b
12 55.0 ± 3.6b 47.5 ± 3.7b 65.0 ± 4.8b
a Mean ± SD, all points of mean percent inhibition were calculated as mentioned in the text with 8–11 rats per data point except for 20 mg/kg
dose groups for ZM4 and ZM5 that had 4 rats per inhibition point.
b p< 0.05 when compared to control rats.
c p< 0.05 when compared to Ibuprofen and Diclofenac (10 mg/kg) and Celecoxib (6 mg/kg).
Table 4 The percent inhibition of COX-1 activity by different
concentration of ZM compounds using COX inhibition
immunoassay (EIA) as compared with Diclofenac. Each value
represents the mean ± SD.
Compound Concentration
2 lM 5 lM 10 lM
ZM2 12.5 ± 7.5 73.7 ± 12.6 25.5 ± 3.5
ZM3 28.10 ± 1.0 72.5 ± 20.5 29.0 ± 1.0
ZM4 30.0 ± 1.0 72.0 ± 18.0 8.00 ± 2.0
ZM5 20.5 ± 0.5 74.5 ± 14.3 20.5 ± 0.5
Diclofenac 73.1 ± 3.1 99.44 ± 0.2 98.0 ± 0.2
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rageenan is more pronounced and independent to dose. Its
activity was comparable to Ibuprofen and Diclofenac (5 and
10 mg/kg), and Celecoxib (12 mg/kg) (p< 0.05).
The anti-inﬂammatory activity of ZM4 was dose- and time-
dependent. A signiﬁcant reduction of carrageenan-induced
inﬂammation was detected only at 20 mg/kg dose of ZM4 at
1, 3 and 5 h post-administration (p< 0.01). On the other
hand, ZM5 produced a varying degree of inhibition of inﬂam-
mation at 1, 3 and 5 h intervals post-carrageenan-induced
inﬂammation. The maximal inhibition of inﬂammation was
observed with 20 mg/kg after 3 and 5 h intervals, which was
equipotent to Diclofenac and Celecoxib (Table 3).
The COX-1 and COX-2 inhibition assay (IC50 values) for
the tested compounds are presented in Table 4. The results
showed that all the compounds ZM2, ZM3, ZM4, and ZM5
showed inhibition of COX-1 and COX-2 with a maximum
inhibition at 5 lM (see Table 5).
However, the inhibition values were less thanDiclofenac and
Celecoxib, as COX-1 andCOX-2 inhibitors. All of the ZM com-
pounds exhibited a bell-shaped inhibition curve being the max-
imum at 5 lM and to a lesser extent at 2 and 10 lM. The best
response was by ZM4 for COX-2 inhibition ranging from
27.5%, 90.5%, and 44.0%, for 2, 5, and 10 lM, respectively.
Other ZM compounds such as ZM2, ZM3 and ZM5 exhibited
inhibitory responses for COX-2 more than COX-1 at 10 lM.
5. Discussion
The tested aminoacetylenic isoindoline-1,3-diones (ZM2–5),
except ZM6, were effective in reducing the inﬂammation in-duced by carrageenan in the paw male rats. When the anti-
inﬂammatory activities of some newly synthesized compounds
(ZM2–ZM5) were compared with Ibuprofen, Diclofenac and
Celecoxib at a dose of 10 mg/kg at 3 and 5 h intervals post-oral
administration, it was evident that ZM3 was more effective
(p< 0.05) than Ibuprofen, Diclofenac, and equal to or slightly
more effective than Celecoxib. The order of activity for ZM
compounds at 10 mg/kg dose at 3 and 5 h intervals was as fol-
low: ZM3P ZM5P ZM4P ZM2. This variation in activity
may be attributed to the nature of the cyclic amino groups;
piperidine is preferred over hexamethyleneimine, pyrrolidine,
and the least with the 2-methyl piperidine. Such difference
may be rationalized on differences in ring size, lipophilicity
and conformational stability of the cyclic amine. Steric factor
neighboring the basic nitrogen may be the reason in decreasing
the potency and/or absorption as seen in ZM4 relative to ZM3
Table 5 The percent inhibition of COX-2 activity by different
concentration of ZM compounds using COX inhibition
immunoassay (EIA) as compared with Celecoxib. Each value
represents the mean ± SD.
Compound Concentration
2 lM 5 lM 10 lM
ZM2 4.0 ± 1.5 79.0 ± 8.0 34.0 ± 5.0
ZM3 8.5 ± 1.0 85.0 ± 11.0 41.0 ± 6.0
ZM4 27.5 ± 1.5 90.5 ± 6.1 44.0 ± 4.0
ZM5 21.5 ± 1.5 85.5 ± 9.0 32.5 ± 2.5
Celecoxib 70.0 ± 0.0 97.5 ± 1.5 93.5 ± 4.5
1030 J.A. Al-Qaisi et al.and inactivity of ZM6. However, higher doses of ZM4 (20 mg/
kg) exhibited signiﬁcant inhibition at 1 h post-administration
which persisted up to 5 h in addition to its low IC50 against
COX-1 and COX-2 activities. This latter phenomenon needs
further investigation.
The inhibitory activities of ZM compounds to COX-1 and
COX-2 enzyme but were maximal at 5 lM concentration for
all ZM compounds and Diclofenac and Celecoxib. However,
all tested ZM compounds (ZM2–5) showed lower inhibitory
activities than Diclofenac and Celecoxib as selective Cox-1
and COX-2 inhibitors, respectively. The basic aminoacetylenic
isoindolines-1,3-diones showed slightly higher inhibitory activ-
ity COX-2 as compared to COX-1. The relative orders of
inhibitory activities of ZM compounds to COX-1 and COX-
2 were ZM2P ZM5P ZM3P ZM4 and ZM4P ZM5P
ZM3P ZM2, respectively. The differences in the order of
inhibitory activity of ZM compounds to COX-1 or COX-2
were varied from the % of inﬂammation inhibition. Such var-
iation may be attributed to different factors such as absorption
and metabolism in vivo in addition to their ability to induce
anti-inﬂammatory cytokines that would enhance the anti-
inﬂammatory activities.6. Conclusion
In conclusion, the new series of basic aminoacetylenic isoindo-
lines showed signiﬁcant activity as anti-inﬂammatory agents
and as COX-1 and COX-2 inhibitors. These observed anti-
inﬂammatory effects should open the door for compounds
other than those acidic or enolic drugs currently available on
the market as anti-inﬂammatory agents. Furthermore, recent
investigations preferred compounds that block COX-1,
COX-2 and LOX enzymes (Ranatunge et al., 2004). Some of
these properties are shown in this series of compounds whichnecessitate further investigation to test their possible inhibitory
activity toward lipoxygenase enzyme.References
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